Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$6.43
+1.3%
$6.92
$5.28
$14.38
$528.19M0.86452,491 shs278,962 shs
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.10
$4.65
$13.13
$1.10B1.471.14 million shs19.38 million shs
Inari Medical, Inc. stock logo
NARI
Inari Medical
$79.97
$79.97
$39.76
$79.99
$4.68B1.021.39 million shsN/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
0.00%-4.17%-8.01%-33.37%+10.48%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.61%+129.51%
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.00%0.00%0.00%0.00%+76.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
3.0563 of 5 stars
3.30.00.00.01.54.21.3
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.3053 of 5 stars
1.10.00.00.00.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.67
Moderate Buy$14.33122.91% Upside
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00
N/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.14
Hold$69.22-13.44% Downside

Current Analyst Ratings Breakdown

Latest CMD, NARI, FNA, and BVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$15.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$567.70M0.93$0.51 per share12.58$2.80 per share2.30
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M9.48$0.09 per share906.95$8.07 per share9.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$0.48N/A13.98N/A-7.11%15.61%4.01%N/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
1.77
1.40

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.14 million54.46 millionNot Optionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
80058.54 million52.34 millionOptionable

Recent News About These Companies

The top nitinol cardiac medtech news of 2025 (so far)
8 spine, orthopedic acquisitions in Q1
Stryker grows cardiovascular division with Inari Medical acquisition
Stryker Completes Acquisition of Inari
Stryker concludes Inari Medical acquisition for $4.9bn
Stryker completes Inari Medical acquisition

Media Sentiment Over Time

Top Headlines

View All Headlines
Bioventus stock logo

Bioventus NYSE:BVS

$6.43 +0.08 (+1.26%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$6.52 +0.10 (+1.48%)
As of 06/18/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Cantel Medical stock logo

Cantel Medical NYSE:CMD

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Inari Medical stock logo

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)
As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.